FORMATION DISCLOSURE CITATION SERIAL NO. 09/940,165 ATTY, DOCKET NO. PC10616A APPLICANT David B. MacLean (Use several sheets if necessary) **GROUP** 1614 FILING DATE August 27, 2001 U.S. PATENT DOCUMENTS DATE NAME CLASS SUBCLASS EXAMINER INITIAL DOCUMENT NUMBER FOREIGN PATENT DOCUMENTS COUNTRY CLASS SUBCLASS DATE DOCUMENT NUMBER YES 4/26/00 European C07D 471/04 ΕP 9 12/30/98 International C07K 5/023 9 wo 5 8 C07K 5/06 International 12/30/98 wo 9 A61K 31/445 3/7/02 International wo 2 A61K 31/12 3/6/02 0 3 European EΡ 8 38/27 10/31/01 A61K European OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) EP Search Report EP 01307229 DATE CONSIDERED EXAMINER EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

wo

9

DEC 0 3 2001 N DISCLOSURE CITATION ATTY. DOCKET NO. PC10616ATMC **SERIAL NO** (Use several sheets if necessary) APPLICANT David B. MacLean FILING DATE August 27, 2001 **GROUP** 1614 **U.S. PATENT DOCUMENTS** EXAMINER INITIAL DOCUMENT NUMBER NAME SUBCLASS FILING DATE IF APPROPRIATE US 0 6 8/22/00 P. A. Carpino, et al. US 7 5 9 9 7 7/6/99 T. K. Hansen, et al. US 5 7 2 3 6 3/3/98 P. G. Houghton, et US 8 0 3 11/24/98 E. V. Cauter, et al. US 9 5 8/31/99 V. L. Fuh, et al. 5 9 8 9/7/99 A. Sommer, et al. US 5 7 7 3 6/30/98 P. A. Hipskind, et al. US 3 3/3/98 H. R. Higley, et al. **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER DATE COUNTRY TRANSLATION CLASS SUBCLASS YES NO WO 0 1/14/99 wo 9 5 0 11/16/95 wo 0 <u>-</u> 1/14/99 WO 9 0 1/14/99 WO 9 9 · 1/14/99 wo 9 3 6 9 6/23/94 wo 0 0 2 0 9/3/00 WO 0 2 11/27/97 WO 9 7 3 6 9 나 7/10/97 wo 8 8 7 / 12/30/98 wo 9 9 5 6 6 / 12/23/99 8 wo 9 8 12/23/99 ow 9 7 4 8 12/24/97

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Chronopharmacology of Growth Hormone and Related Peptides, Advanced Drug Delivery Reviews; 6, (1991), pg. 57-82.

2 / 5/20/99.

6/18/04

## RECEIVED

DEC 0 4 2001

(8)	TECH CENTER 1600/2900				
INFORMATION DISCLOSURE CITATION	ATTY. DOCK	ET NO. PC10616ATM			
(Use several sheets in coessand					
(USB Several Sheets II NATA)		August 27, 2001	GROUP	P 1614	
R. G. Clark, et al., Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats; Journal of Endogrinology; (1985), pg. 53-61.					
R. G. Clark, et al., Paradoxical growth	R. G. Clark, et al., Paradoxical growth-promoting effects induced by patterned infusions of somatostatin in female rats, Endocrinology; (1988), pg. 2675-2682.				
Evelien F. Gevers, et al., Growth, Growth Hormone (GH)-Binding Protein, and GH Receptors are Differentially Regulated by Peak and Trough Components of the GH Secretory Pattern in the Rat, Endocrinology; (1996), pg. 1013-1018.					
Wendy C. Huhn, et al., Twenty-four-hour Growth Hormone (GH)-releasing Peptide (GHRP) Infusion Enhances Pulsatile GH Secretion and Specifically Attenuates the Response to a Subsequent GHRP Bolus; Journal of Clinical Endocrinology and Metabolism; (1993), pg. 1202-1207.					
Mark L. Hartman, et al., Temporal structure of in vivo growth hormone secretory events in humans, The American Physiological Society; (1991), pg. E101-E110.					
B. B. Bercu, et al., Sex Differences in Endocrinology; (1991), pg. 2592-259	Growth Hormone	(GH) Secretion by Rats Adm	ninistered GH-Rele	easing Hexapeptide,	
R. G. Smith, et al., Peptidomimetic R		Hormone Secretion, Endoc	rine Reviews; (199	97), pg. 621-645.	
G. Van Den Berghe, et al., The Some Hormone and GH-Releasing Peptide	atotronic Axis in Cn	tical Illness: Effect of Contin	uous Growth Horm	mone (GH)-Releasing	
				<del></del>	
EXAMINER Alle		DATE CONSIDERED	6/18/0	04	
EXAMINER: Initial if reference considered, whether or not citation is in confenext communication to applicant.	ormance with MPEP 609;	Draw line through citation if not in cor	atormance and not consid	idered. Include copy of this form with	

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE